nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Beclomethasone—psoriasis	0.104	0.197	CbGbCtD
Paliperidone—CYP2D6—Hydroxyurea—psoriasis	0.0485	0.0914	CbGbCtD
Paliperidone—CYP3A5—Mycophenolate mofetil—psoriasis	0.0416	0.0783	CbGbCtD
Paliperidone—CYP3A4—Calcitriol—psoriasis	0.0363	0.0683	CbGbCtD
Paliperidone—CYP3A5—Hydrocortisone—psoriasis	0.0334	0.0628	CbGbCtD
Paliperidone—CYP3A5—Cyclosporine—psoriasis	0.0315	0.0593	CbGbCtD
Paliperidone—CYP2D6—Cholecalciferol—psoriasis	0.0294	0.0554	CbGbCtD
Paliperidone—CYP3A4—Methoxsalen—psoriasis	0.0282	0.0531	CbGbCtD
Paliperidone—CYP3A5—Dexamethasone—psoriasis	0.0208	0.0391	CbGbCtD
Paliperidone—CYP2D6—Cyclosporine—psoriasis	0.0193	0.0364	CbGbCtD
Paliperidone—CYP3A4—Cholecalciferol—psoriasis	0.0187	0.0352	CbGbCtD
Paliperidone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0162	0.0305	CbGbCtD
Paliperidone—CYP3A4—Triamcinolone—psoriasis	0.0162	0.0305	CbGbCtD
Paliperidone—CYP3A4—Betamethasone—psoriasis	0.0139	0.0262	CbGbCtD
Paliperidone—CYP3A4—Prednisolone—psoriasis	0.0137	0.0258	CbGbCtD
Paliperidone—CYP3A4—Hydrocortisone—psoriasis	0.013	0.0245	CbGbCtD
Paliperidone—CYP3A4—Prednisone—psoriasis	0.013	0.0244	CbGbCtD
Paliperidone—CYP2D6—Dexamethasone—psoriasis	0.0127	0.024	CbGbCtD
Paliperidone—CYP3A4—Cyclosporine—psoriasis	0.0123	0.0231	CbGbCtD
Paliperidone—CYP3A4—Dexamethasone—psoriasis	0.00809	0.0152	CbGbCtD
Paliperidone—Body temperature increased—Cyclosporine—psoriasis	0.000125	0.000287	CcSEcCtD
Paliperidone—Anxiety—Betamethasone—psoriasis	0.000124	0.000287	CcSEcCtD
Paliperidone—Anxiety—Dexamethasone—psoriasis	0.000124	0.000287	CcSEcCtD
Paliperidone—Vomiting—Mycophenolic acid—psoriasis	0.000124	0.000286	CcSEcCtD
Paliperidone—Discomfort—Betamethasone—psoriasis	0.000123	0.000284	CcSEcCtD
Paliperidone—Discomfort—Dexamethasone—psoriasis	0.000123	0.000284	CcSEcCtD
Paliperidone—Dyspepsia—Hydrocortisone—psoriasis	0.000123	0.000284	CcSEcCtD
Paliperidone—Rash—Mycophenolic acid—psoriasis	0.000123	0.000283	CcSEcCtD
Paliperidone—Dermatitis—Mycophenolic acid—psoriasis	0.000123	0.000283	CcSEcCtD
Paliperidone—Pain—Prednisolone—psoriasis	0.000123	0.000283	CcSEcCtD
Paliperidone—Urticaria—Mycophenolate mofetil—psoriasis	0.000122	0.000282	CcSEcCtD
Paliperidone—Headache—Mycophenolic acid—psoriasis	0.000122	0.000281	CcSEcCtD
Paliperidone—Decreased appetite—Hydrocortisone—psoriasis	0.000122	0.000281	CcSEcCtD
Paliperidone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000121	0.00028	CcSEcCtD
Paliperidone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000121	0.00028	CcSEcCtD
Paliperidone—Urinary tract disorder—Methotrexate—psoriasis	0.000121	0.000279	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000121	0.000279	CcSEcCtD
Paliperidone—Fatigue—Hydrocortisone—psoriasis	0.000121	0.000278	CcSEcCtD
Paliperidone—Vision blurred—Prednisone—psoriasis	0.00012	0.000277	CcSEcCtD
Paliperidone—Urethral disorder—Methotrexate—psoriasis	0.00012	0.000277	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00012	0.000277	CcSEcCtD
Paliperidone—Pain—Hydrocortisone—psoriasis	0.00012	0.000276	CcSEcCtD
Paliperidone—Oedema—Dexamethasone—psoriasis	0.00012	0.000276	CcSEcCtD
Paliperidone—Anaphylactic shock—Dexamethasone—psoriasis	0.00012	0.000276	CcSEcCtD
Paliperidone—Oedema—Betamethasone—psoriasis	0.00012	0.000276	CcSEcCtD
Paliperidone—Anaphylactic shock—Betamethasone—psoriasis	0.00012	0.000276	CcSEcCtD
Paliperidone—Insomnia—Triamcinolone—psoriasis	0.000119	0.000275	CcSEcCtD
Paliperidone—Infection—Dexamethasone—psoriasis	0.000119	0.000274	CcSEcCtD
Paliperidone—Infection—Betamethasone—psoriasis	0.000119	0.000274	CcSEcCtD
Paliperidone—Ill-defined disorder—Prednisone—psoriasis	0.000118	0.000273	CcSEcCtD
Paliperidone—Paraesthesia—Triamcinolone—psoriasis	0.000118	0.000273	CcSEcCtD
Paliperidone—Feeling abnormal—Prednisolone—psoriasis	0.000118	0.000272	CcSEcCtD
Paliperidone—Anaemia—Prednisone—psoriasis	0.000118	0.000272	CcSEcCtD
Paliperidone—Shock—Betamethasone—psoriasis	0.000118	0.000271	CcSEcCtD
Paliperidone—Shock—Dexamethasone—psoriasis	0.000118	0.000271	CcSEcCtD
Paliperidone—Dyspnoea—Triamcinolone—psoriasis	0.000118	0.000271	CcSEcCtD
Paliperidone—Nervous system disorder—Betamethasone—psoriasis	0.000117	0.000271	CcSEcCtD
Paliperidone—Nervous system disorder—Dexamethasone—psoriasis	0.000117	0.000271	CcSEcCtD
Paliperidone—Agitation—Prednisone—psoriasis	0.000117	0.00027	CcSEcCtD
Paliperidone—Thrombocytopenia—Betamethasone—psoriasis	0.000117	0.00027	CcSEcCtD
Paliperidone—Thrombocytopenia—Dexamethasone—psoriasis	0.000117	0.00027	CcSEcCtD
Paliperidone—Tachycardia—Betamethasone—psoriasis	0.000117	0.000269	CcSEcCtD
Paliperidone—Tachycardia—Dexamethasone—psoriasis	0.000117	0.000269	CcSEcCtD
Paliperidone—Angioedema—Prednisone—psoriasis	0.000117	0.000269	CcSEcCtD
Paliperidone—Hypersensitivity—Cyclosporine—psoriasis	0.000116	0.000268	CcSEcCtD
Paliperidone—Dyspepsia—Triamcinolone—psoriasis	0.000116	0.000268	CcSEcCtD
Paliperidone—Nausea—Mycophenolic acid—psoriasis	0.000116	0.000267	CcSEcCtD
Paliperidone—Feeling abnormal—Hydrocortisone—psoriasis	0.000115	0.000266	CcSEcCtD
Paliperidone—Malaise—Prednisone—psoriasis	0.000115	0.000265	CcSEcCtD
Paliperidone—Vertigo—Prednisone—psoriasis	0.000115	0.000264	CcSEcCtD
Paliperidone—Eye disorder—Methotrexate—psoriasis	0.000114	0.000264	CcSEcCtD
Paliperidone—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000114	0.000264	CcSEcCtD
Paliperidone—Syncope—Prednisone—psoriasis	0.000114	0.000264	CcSEcCtD
Paliperidone—Tinnitus—Methotrexate—psoriasis	0.000114	0.000263	CcSEcCtD
Paliperidone—Anorexia—Dexamethasone—psoriasis	0.000114	0.000263	CcSEcCtD
Paliperidone—Anorexia—Betamethasone—psoriasis	0.000114	0.000263	CcSEcCtD
Paliperidone—Urticaria—Prednisolone—psoriasis	0.000114	0.000263	CcSEcCtD
Paliperidone—Cardiac disorder—Methotrexate—psoriasis	0.000114	0.000262	CcSEcCtD
Paliperidone—Fatigue—Triamcinolone—psoriasis	0.000114	0.000262	CcSEcCtD
Paliperidone—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000113	0.000261	CcSEcCtD
Paliperidone—Asthenia—Cyclosporine—psoriasis	0.000113	0.000261	CcSEcCtD
Paliperidone—Pain—Triamcinolone—psoriasis	0.000113	0.00026	CcSEcCtD
Paliperidone—Loss of consciousness—Prednisone—psoriasis	0.000112	0.000259	CcSEcCtD
Paliperidone—Hypotension—Betamethasone—psoriasis	0.000112	0.000258	CcSEcCtD
Paliperidone—Hypotension—Dexamethasone—psoriasis	0.000112	0.000258	CcSEcCtD
Paliperidone—Pruritus—Cyclosporine—psoriasis	0.000111	0.000257	CcSEcCtD
Paliperidone—Urticaria—Hydrocortisone—psoriasis	0.000111	0.000256	CcSEcCtD
Paliperidone—Angiopathy—Methotrexate—psoriasis	0.000111	0.000256	CcSEcCtD
Paliperidone—Immune system disorder—Methotrexate—psoriasis	0.000111	0.000255	CcSEcCtD
Paliperidone—Body temperature increased—Hydrocortisone—psoriasis	0.000111	0.000255	CcSEcCtD
Paliperidone—Abdominal pain—Hydrocortisone—psoriasis	0.000111	0.000255	CcSEcCtD
Paliperidone—Convulsion—Prednisone—psoriasis	0.000111	0.000255	CcSEcCtD
Paliperidone—Mediastinal disorder—Methotrexate—psoriasis	0.00011	0.000255	CcSEcCtD
Paliperidone—Asthenia—Mycophenolate mofetil—psoriasis	0.00011	0.000254	CcSEcCtD
Paliperidone—Hypertension—Prednisone—psoriasis	0.00011	0.000254	CcSEcCtD
Paliperidone—Chills—Methotrexate—psoriasis	0.00011	0.000254	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000109	0.000251	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000109	0.000251	CcSEcCtD
Paliperidone—Pruritus—Mycophenolate mofetil—psoriasis	0.000109	0.000251	CcSEcCtD
Paliperidone—Arthralgia—Prednisone—psoriasis	0.000109	0.000251	CcSEcCtD
Paliperidone—Myalgia—Prednisone—psoriasis	0.000109	0.000251	CcSEcCtD
Paliperidone—Feeling abnormal—Triamcinolone—psoriasis	0.000109	0.000251	CcSEcCtD
Paliperidone—Anxiety—Prednisone—psoriasis	0.000108	0.00025	CcSEcCtD
Paliperidone—Alopecia—Methotrexate—psoriasis	0.000108	0.00025	CcSEcCtD
Paliperidone—Insomnia—Dexamethasone—psoriasis	0.000108	0.000249	CcSEcCtD
Paliperidone—Insomnia—Betamethasone—psoriasis	0.000108	0.000249	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000108	0.000249	CcSEcCtD
Paliperidone—Diarrhoea—Cyclosporine—psoriasis	0.000108	0.000249	CcSEcCtD
Paliperidone—Paraesthesia—Betamethasone—psoriasis	0.000107	0.000248	CcSEcCtD
Paliperidone—Paraesthesia—Dexamethasone—psoriasis	0.000107	0.000248	CcSEcCtD
Paliperidone—Discomfort—Prednisone—psoriasis	0.000107	0.000248	CcSEcCtD
Paliperidone—Mental disorder—Methotrexate—psoriasis	0.000107	0.000248	CcSEcCtD
Paliperidone—Malnutrition—Methotrexate—psoriasis	0.000107	0.000246	CcSEcCtD
Paliperidone—Erythema—Methotrexate—psoriasis	0.000107	0.000246	CcSEcCtD
Paliperidone—Hypersensitivity—Prednisolone—psoriasis	0.000106	0.000244	CcSEcCtD
Paliperidone—Dyspepsia—Betamethasone—psoriasis	0.000105	0.000243	CcSEcCtD
Paliperidone—Dyspepsia—Dexamethasone—psoriasis	0.000105	0.000243	CcSEcCtD
Paliperidone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000105	0.000242	CcSEcCtD
Paliperidone—Urticaria—Triamcinolone—psoriasis	0.000105	0.000242	CcSEcCtD
Paliperidone—Dysgeusia—Methotrexate—psoriasis	0.000104	0.000241	CcSEcCtD
Paliperidone—Body temperature increased—Triamcinolone—psoriasis	0.000104	0.00024	CcSEcCtD
Paliperidone—Dizziness—Cyclosporine—psoriasis	0.000104	0.00024	CcSEcCtD
Paliperidone—Anaphylactic shock—Prednisone—psoriasis	0.000104	0.00024	CcSEcCtD
Paliperidone—Oedema—Prednisone—psoriasis	0.000104	0.00024	CcSEcCtD
Paliperidone—Decreased appetite—Betamethasone—psoriasis	0.000104	0.00024	CcSEcCtD
Paliperidone—Decreased appetite—Dexamethasone—psoriasis	0.000104	0.00024	CcSEcCtD
Paliperidone—Infection—Prednisone—psoriasis	0.000103	0.000239	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000103	0.000238	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Betamethasone—psoriasis	0.000103	0.000238	CcSEcCtD
Paliperidone—Back pain—Methotrexate—psoriasis	0.000103	0.000238	CcSEcCtD
Paliperidone—Hypersensitivity—Hydrocortisone—psoriasis	0.000103	0.000238	CcSEcCtD
Paliperidone—Fatigue—Betamethasone—psoriasis	0.000103	0.000238	CcSEcCtD
Paliperidone—Fatigue—Dexamethasone—psoriasis	0.000103	0.000238	CcSEcCtD
Paliperidone—Shock—Prednisone—psoriasis	0.000102	0.000236	CcSEcCtD
Paliperidone—Pain—Dexamethasone—psoriasis	0.000102	0.000236	CcSEcCtD
Paliperidone—Pain—Betamethasone—psoriasis	0.000102	0.000236	CcSEcCtD
Paliperidone—Nervous system disorder—Prednisone—psoriasis	0.000102	0.000236	CcSEcCtD
Paliperidone—Tachycardia—Prednisone—psoriasis	0.000102	0.000234	CcSEcCtD
Paliperidone—Dizziness—Mycophenolate mofetil—psoriasis	0.000102	0.000234	CcSEcCtD
Paliperidone—Skin disorder—Prednisone—psoriasis	0.000101	0.000233	CcSEcCtD
Paliperidone—Vision blurred—Methotrexate—psoriasis	0.000101	0.000232	CcSEcCtD
Paliperidone—Asthenia—Hydrocortisone—psoriasis	0.0001	0.000232	CcSEcCtD
Paliperidone—Vomiting—Cyclosporine—psoriasis	0.0001	0.000231	CcSEcCtD
Paliperidone—Rash—Cyclosporine—psoriasis	9.93e-05	0.000229	CcSEcCtD
Paliperidone—Anorexia—Prednisone—psoriasis	9.93e-05	0.000229	CcSEcCtD
Paliperidone—Dermatitis—Cyclosporine—psoriasis	9.92e-05	0.000229	CcSEcCtD
Paliperidone—Pruritus—Hydrocortisone—psoriasis	9.9e-05	0.000228	CcSEcCtD
Paliperidone—Ill-defined disorder—Methotrexate—psoriasis	9.89e-05	0.000228	CcSEcCtD
Paliperidone—Headache—Cyclosporine—psoriasis	9.87e-05	0.000228	CcSEcCtD
Paliperidone—Anaemia—Methotrexate—psoriasis	9.86e-05	0.000227	CcSEcCtD
Paliperidone—Feeling abnormal—Dexamethasone—psoriasis	9.85e-05	0.000227	CcSEcCtD
Paliperidone—Feeling abnormal—Betamethasone—psoriasis	9.85e-05	0.000227	CcSEcCtD
Paliperidone—Gastrointestinal pain—Dexamethasone—psoriasis	9.78e-05	0.000226	CcSEcCtD
Paliperidone—Gastrointestinal pain—Betamethasone—psoriasis	9.78e-05	0.000226	CcSEcCtD
Paliperidone—Vomiting—Mycophenolate mofetil—psoriasis	9.77e-05	0.000225	CcSEcCtD
Paliperidone—Hypersensitivity—Triamcinolone—psoriasis	9.71e-05	0.000224	CcSEcCtD
Paliperidone—Rash—Mycophenolate mofetil—psoriasis	9.69e-05	0.000223	CcSEcCtD
Paliperidone—Dermatitis—Mycophenolate mofetil—psoriasis	9.68e-05	0.000223	CcSEcCtD
Paliperidone—Headache—Mycophenolate mofetil—psoriasis	9.62e-05	0.000222	CcSEcCtD
Paliperidone—Malaise—Methotrexate—psoriasis	9.62e-05	0.000222	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—psoriasis	9.58e-05	0.000221	CcSEcCtD
Paliperidone—Diarrhoea—Hydrocortisone—psoriasis	9.58e-05	0.000221	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—psoriasis	9.55e-05	0.00022	CcSEcCtD
Paliperidone—Urticaria—Betamethasone—psoriasis	9.5e-05	0.000219	CcSEcCtD
Paliperidone—Urticaria—Dexamethasone—psoriasis	9.5e-05	0.000219	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Prednisone—psoriasis	9.49e-05	0.000219	CcSEcCtD
Paliperidone—Dizziness—Prednisolone—psoriasis	9.48e-05	0.000219	CcSEcCtD
Paliperidone—Asthenia—Triamcinolone—psoriasis	9.46e-05	0.000218	CcSEcCtD
Paliperidone—Abdominal pain—Dexamethasone—psoriasis	9.45e-05	0.000218	CcSEcCtD
Paliperidone—Abdominal pain—Betamethasone—psoriasis	9.45e-05	0.000218	CcSEcCtD
Paliperidone—Body temperature increased—Dexamethasone—psoriasis	9.45e-05	0.000218	CcSEcCtD
Paliperidone—Body temperature increased—Betamethasone—psoriasis	9.45e-05	0.000218	CcSEcCtD
Paliperidone—Insomnia—Prednisone—psoriasis	9.42e-05	0.000217	CcSEcCtD
Paliperidone—Nausea—Cyclosporine—psoriasis	9.36e-05	0.000216	CcSEcCtD
Paliperidone—Paraesthesia—Prednisone—psoriasis	9.35e-05	0.000216	CcSEcCtD
Paliperidone—Pruritus—Triamcinolone—psoriasis	9.32e-05	0.000215	CcSEcCtD
Paliperidone—Cough—Methotrexate—psoriasis	9.31e-05	0.000215	CcSEcCtD
Paliperidone—Dizziness—Hydrocortisone—psoriasis	9.26e-05	0.000214	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—psoriasis	9.24e-05	0.000213	CcSEcCtD
Paliperidone—Dyspepsia—Prednisone—psoriasis	9.17e-05	0.000211	CcSEcCtD
Paliperidone—Nausea—Mycophenolate mofetil—psoriasis	9.13e-05	0.000211	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—psoriasis	9.08e-05	0.000209	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—psoriasis	9.08e-05	0.000209	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—psoriasis	9.08e-05	0.000209	CcSEcCtD
Paliperidone—Decreased appetite—Prednisone—psoriasis	9.05e-05	0.000209	CcSEcCtD
Paliperidone—Rash—Prednisolone—psoriasis	9.04e-05	0.000208	CcSEcCtD
Paliperidone—Dermatitis—Prednisolone—psoriasis	9.03e-05	0.000208	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.02e-05	0.000208	CcSEcCtD
Paliperidone—Fatigue—Prednisone—psoriasis	8.98e-05	0.000207	CcSEcCtD
Paliperidone—Headache—Prednisolone—psoriasis	8.98e-05	0.000207	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—psoriasis	8.97e-05	0.000207	CcSEcCtD
Paliperidone—Constipation—Prednisone—psoriasis	8.91e-05	0.000205	CcSEcCtD
Paliperidone—Vomiting—Hydrocortisone—psoriasis	8.9e-05	0.000205	CcSEcCtD
Paliperidone—Rash—Hydrocortisone—psoriasis	8.83e-05	0.000204	CcSEcCtD
Paliperidone—Dermatitis—Hydrocortisone—psoriasis	8.82e-05	0.000203	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—psoriasis	8.78e-05	0.000202	CcSEcCtD
Paliperidone—Headache—Hydrocortisone—psoriasis	8.77e-05	0.000202	CcSEcCtD
Paliperidone—Dizziness—Triamcinolone—psoriasis	8.72e-05	0.000201	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—psoriasis	8.7e-05	0.000201	CcSEcCtD
Paliperidone—Infection—Methotrexate—psoriasis	8.65e-05	0.000199	CcSEcCtD
Paliperidone—Feeling abnormal—Prednisone—psoriasis	8.58e-05	0.000198	CcSEcCtD
Paliperidone—Asthenia—Dexamethasone—psoriasis	8.58e-05	0.000198	CcSEcCtD
Paliperidone—Asthenia—Betamethasone—psoriasis	8.58e-05	0.000198	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—psoriasis	8.54e-05	0.000197	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—psoriasis	8.52e-05	0.000197	CcSEcCtD
Paliperidone—Gastrointestinal pain—Prednisone—psoriasis	8.52e-05	0.000196	CcSEcCtD
Paliperidone—Nausea—Prednisolone—psoriasis	8.51e-05	0.000196	CcSEcCtD
Paliperidone—Pruritus—Betamethasone—psoriasis	8.46e-05	0.000195	CcSEcCtD
Paliperidone—Pruritus—Dexamethasone—psoriasis	8.46e-05	0.000195	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—psoriasis	8.45e-05	0.000195	CcSEcCtD
Paliperidone—Vomiting—Triamcinolone—psoriasis	8.38e-05	0.000193	CcSEcCtD
Paliperidone—Nausea—Hydrocortisone—psoriasis	8.31e-05	0.000192	CcSEcCtD
Paliperidone—Rash—Triamcinolone—psoriasis	8.31e-05	0.000192	CcSEcCtD
Paliperidone—Dermatitis—Triamcinolone—psoriasis	8.3e-05	0.000192	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—psoriasis	8.3e-05	0.000191	CcSEcCtD
Paliperidone—Urticaria—Prednisone—psoriasis	8.27e-05	0.000191	CcSEcCtD
Paliperidone—Headache—Triamcinolone—psoriasis	8.26e-05	0.00019	CcSEcCtD
Paliperidone—Abdominal pain—Prednisone—psoriasis	8.23e-05	0.00019	CcSEcCtD
Paliperidone—Body temperature increased—Prednisone—psoriasis	8.23e-05	0.00019	CcSEcCtD
Paliperidone—Diarrhoea—Betamethasone—psoriasis	8.18e-05	0.000189	CcSEcCtD
Paliperidone—Diarrhoea—Dexamethasone—psoriasis	8.18e-05	0.000189	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—psoriasis	8.13e-05	0.000188	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—psoriasis	7.93e-05	0.000183	CcSEcCtD
Paliperidone—Dizziness—Betamethasone—psoriasis	7.91e-05	0.000182	CcSEcCtD
Paliperidone—Dizziness—Dexamethasone—psoriasis	7.91e-05	0.000182	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—psoriasis	7.87e-05	0.000182	CcSEcCtD
Paliperidone—Nausea—Triamcinolone—psoriasis	7.83e-05	0.000181	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—psoriasis	7.82e-05	0.00018	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—psoriasis	7.76e-05	0.000179	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—psoriasis	7.74e-05	0.000178	CcSEcCtD
Paliperidone—Hypersensitivity—Prednisone—psoriasis	7.67e-05	0.000177	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—psoriasis	7.66e-05	0.000177	CcSEcCtD
Paliperidone—Vomiting—Dexamethasone—psoriasis	7.6e-05	0.000175	CcSEcCtD
Paliperidone—Vomiting—Betamethasone—psoriasis	7.6e-05	0.000175	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—psoriasis	7.57e-05	0.000175	CcSEcCtD
Paliperidone—Rash—Dexamethasone—psoriasis	7.54e-05	0.000174	CcSEcCtD
Paliperidone—Rash—Betamethasone—psoriasis	7.54e-05	0.000174	CcSEcCtD
Paliperidone—Dermatitis—Betamethasone—psoriasis	7.53e-05	0.000174	CcSEcCtD
Paliperidone—Dermatitis—Dexamethasone—psoriasis	7.53e-05	0.000174	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—psoriasis	7.51e-05	0.000173	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—psoriasis	7.5e-05	0.000173	CcSEcCtD
Paliperidone—Headache—Betamethasone—psoriasis	7.49e-05	0.000173	CcSEcCtD
Paliperidone—Headache—Dexamethasone—psoriasis	7.49e-05	0.000173	CcSEcCtD
Paliperidone—Asthenia—Prednisone—psoriasis	7.47e-05	0.000172	CcSEcCtD
Paliperidone—Pain—Methotrexate—psoriasis	7.44e-05	0.000172	CcSEcCtD
Paliperidone—Pruritus—Prednisone—psoriasis	7.37e-05	0.00017	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—psoriasis	7.17e-05	0.000165	CcSEcCtD
Paliperidone—Diarrhoea—Prednisone—psoriasis	7.13e-05	0.000164	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—psoriasis	7.12e-05	0.000164	CcSEcCtD
Paliperidone—Nausea—Betamethasone—psoriasis	7.1e-05	0.000164	CcSEcCtD
Paliperidone—Nausea—Dexamethasone—psoriasis	7.1e-05	0.000164	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—psoriasis	6.91e-05	0.000159	CcSEcCtD
Paliperidone—Dizziness—Prednisone—psoriasis	6.89e-05	0.000159	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—psoriasis	6.88e-05	0.000159	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—psoriasis	6.88e-05	0.000159	CcSEcCtD
Paliperidone—Vomiting—Prednisone—psoriasis	6.62e-05	0.000153	CcSEcCtD
Paliperidone—Rash—Prednisone—psoriasis	6.57e-05	0.000151	CcSEcCtD
Paliperidone—Dermatitis—Prednisone—psoriasis	6.56e-05	0.000151	CcSEcCtD
Paliperidone—Headache—Prednisone—psoriasis	6.52e-05	0.00015	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—psoriasis	6.41e-05	0.000148	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—psoriasis	6.24e-05	0.000144	CcSEcCtD
Paliperidone—Nausea—Prednisone—psoriasis	6.19e-05	0.000143	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—psoriasis	6.16e-05	0.000142	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—psoriasis	5.96e-05	0.000137	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—psoriasis	5.76e-05	0.000133	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—psoriasis	5.53e-05	0.000128	CcSEcCtD
Paliperidone—Rash—Methotrexate—psoriasis	5.49e-05	0.000127	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—psoriasis	5.48e-05	0.000126	CcSEcCtD
Paliperidone—Headache—Methotrexate—psoriasis	5.45e-05	0.000126	CcSEcCtD
Paliperidone—Nausea—Methotrexate—psoriasis	5.17e-05	0.000119	CcSEcCtD
Paliperidone—HTR1D—Signaling by GPCR—CXCL8—psoriasis	1.39e-05	0.000394	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—TYK2—psoriasis	1.38e-05	0.000393	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—CAT—psoriasis	1.37e-05	0.000389	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—TYK2—psoriasis	1.36e-05	0.000387	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—CXCL8—psoriasis	1.36e-05	0.000386	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—CXCL8—psoriasis	1.34e-05	0.00038	CbGpPWpGaD
Paliperidone—DRD1—GPCR downstream signaling—CXCL8—psoriasis	1.33e-05	0.000376	CbGpPWpGaD
Paliperidone—DRD3—GPCR downstream signaling—CXCL8—psoriasis	1.31e-05	0.000371	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SOCS1—psoriasis	1.29e-05	0.000367	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SOCS1—psoriasis	1.25e-05	0.000354	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SOCS1—psoriasis	1.24e-05	0.000352	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—APOE—psoriasis	1.23e-05	0.00035	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—LEP—psoriasis	1.23e-05	0.00035	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—TYK2—psoriasis	1.23e-05	0.00035	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—LEP—psoriasis	1.21e-05	0.000343	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—APOE—psoriasis	1.21e-05	0.000343	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SOCS1—psoriasis	1.21e-05	0.000343	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—CXCL8—psoriasis	1.2e-05	0.000342	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—TYK2—psoriasis	1.19e-05	0.000338	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—LEP—psoriasis	1.19e-05	0.000338	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—APOE—psoriasis	1.19e-05	0.000338	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—CXCL8—psoriasis	1.19e-05	0.000337	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SOCS1—psoriasis	1.19e-05	0.000337	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—TYK2—psoriasis	1.18e-05	0.000336	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	1.18e-05	0.000335	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CARM1—psoriasis	1.18e-05	0.000335	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—VEGFA—psoriasis	1.15e-05	0.000327	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—TYK2—psoriasis	1.15e-05	0.000327	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—NFKBIA—psoriasis	1.15e-05	0.000326	CbGpPWpGaD
Paliperidone—ADRA2B—Hemostasis—TP53—psoriasis	1.15e-05	0.000326	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	1.14e-05	0.000324	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	1.13e-05	0.000322	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—TYK2—psoriasis	1.13e-05	0.000322	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—NFKBIA—psoriasis	1.13e-05	0.00032	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—CAT—psoriasis	1.11e-05	0.000316	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—NFKBIA—psoriasis	1.11e-05	0.000315	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—CXCL8—psoriasis	1.1e-05	0.000313	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SOCS1—psoriasis	1.1e-05	0.000311	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	1.09e-05	0.000308	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SOCS1—psoriasis	1.08e-05	0.000306	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SOCS1—psoriasis	1.08e-05	0.000305	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	1.07e-05	0.000305	CbGpPWpGaD
Paliperidone—ADRA2C—Hemostasis—TP53—psoriasis	1.07e-05	0.000304	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—APOE—psoriasis	1.07e-05	0.000304	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—LEP—psoriasis	1.07e-05	0.000304	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—APOE—psoriasis	1.07e-05	0.000302	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—LEP—psoriasis	1.06e-05	0.0003	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—APOE—psoriasis	1.06e-05	0.0003	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SOCS1—psoriasis	1.06e-05	0.0003	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.000296	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—CXCL8—psoriasis	1.04e-05	0.000294	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.03e-05	0.000292	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.03e-05	0.000292	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—TYK2—psoriasis	1.03e-05	0.000291	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—CAT—psoriasis	1.02e-05	0.00029	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—TYK2—psoriasis	1.01e-05	0.000286	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	1e-05	0.000284	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1e-05	0.000284	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—NFKBIA—psoriasis	9.98e-06	0.000283	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	9.86e-06	0.00028	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	9.85e-06	0.00028	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—NFKBIA—psoriasis	9.84e-06	0.000279	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—CXCL8—psoriasis	9.83e-06	0.000279	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SOCS1—psoriasis	9.8e-06	0.000278	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	9.65e-06	0.000274	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—LEP—psoriasis	9.54e-06	0.000271	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—APOE—psoriasis	9.54e-06	0.000271	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TYK2—psoriasis	9.42e-06	0.000267	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—TYK2—psoriasis	9.35e-06	0.000265	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PPARG—psoriasis	9.28e-06	0.000263	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TYK2—psoriasis	9.22e-06	0.000262	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—LEP—psoriasis	9.21e-06	0.000261	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—APOE—psoriasis	9.21e-06	0.000261	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—LEP—psoriasis	9.16e-06	0.00026	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—APOE—psoriasis	9.16e-06	0.00026	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—CXCL8—psoriasis	9.09e-06	0.000258	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TYK2—psoriasis	9.08e-06	0.000258	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	8.96e-06	0.000254	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—CXCL8—psoriasis	8.95e-06	0.000254	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—CXCL8—psoriasis	8.93e-06	0.000253	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—APOE—psoriasis	8.91e-06	0.000253	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—LEP—psoriasis	8.91e-06	0.000253	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	8.89e-06	0.000252	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—APOE—psoriasis	8.77e-06	0.000249	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—LEP—psoriasis	8.77e-06	0.000249	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	8.76e-06	0.000249	CbGpPWpGaD
Paliperidone—ADRA2A—Hemostasis—TP53—psoriasis	8.7e-06	0.000247	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—APOE—psoriasis	8.65e-06	0.000246	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NFKBIA—psoriasis	8.58e-06	0.000244	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NFKBIA—psoriasis	8.53e-06	0.000242	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	8.3e-06	0.000236	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—CXCL8—psoriasis	8.2e-06	0.000233	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TYK2—psoriasis	8.17e-06	0.000232	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	8.17e-06	0.000232	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	8.14e-06	0.000231	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—LEP—psoriasis	8.08e-06	0.000229	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—APOE—psoriasis	8.08e-06	0.000229	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TYK2—psoriasis	8.06e-06	0.000229	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—CXCL8—psoriasis	8.03e-06	0.000228	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—LEP—psoriasis	7.95e-06	0.000226	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—APOE—psoriasis	7.95e-06	0.000226	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—LEP—psoriasis	7.94e-06	0.000225	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—APOE—psoriasis	7.94e-06	0.000225	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—APOE—psoriasis	7.93e-06	0.000225	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—CXCL8—psoriasis	7.9e-06	0.000224	CbGpPWpGaD
Paliperidone—HTR1D—Signaling by GPCR—IL6—psoriasis	7.8e-06	0.000221	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—APOE—psoriasis	7.79e-06	0.000221	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—LEP—psoriasis	7.79e-06	0.000221	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CARM1—psoriasis	7.71e-06	0.000219	CbGpPWpGaD
Paliperidone—HTR1B—Signaling by GPCR—IL6—psoriasis	7.64e-06	0.000217	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—JUN—psoriasis	7.62e-06	0.000216	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PPARG—psoriasis	7.54e-06	0.000214	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NFKBIA—psoriasis	7.53e-06	0.000214	CbGpPWpGaD
Paliperidone—DRD4—Signaling by GPCR—IL6—psoriasis	7.51e-06	0.000213	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—JUN—psoriasis	7.47e-06	0.000212	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NFKBIA—psoriasis	7.41e-06	0.00021	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NFKBIA—psoriasis	7.39e-06	0.00021	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—JUN—psoriasis	7.35e-06	0.000209	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—NFKB1—psoriasis	7.34e-06	0.000208	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TYK2—psoriasis	7.28e-06	0.000207	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CAT—psoriasis	7.26e-06	0.000206	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	7.26e-06	0.000206	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—LEP—psoriasis	7.24e-06	0.000205	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—APOE—psoriasis	7.24e-06	0.000205	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—NFKB1—psoriasis	7.19e-06	0.000204	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—CXCL8—psoriasis	7.11e-06	0.000202	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—NFKB1—psoriasis	7.07e-06	0.000201	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TYK2—psoriasis	7.03e-06	0.000199	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—CXCL8—psoriasis	7.02e-06	0.000199	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TYK2—psoriasis	6.99e-06	0.000198	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PPARG—psoriasis	6.91e-06	0.000196	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TYK2—psoriasis	6.8e-06	0.000193	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—IL6—psoriasis	6.76e-06	0.000192	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	6.74e-06	0.000191	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TYK2—psoriasis	6.69e-06	0.00019	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—IL6—psoriasis	6.67e-06	0.000189	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—VEGFA—psoriasis	6.66e-06	0.000189	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—JUN—psoriasis	6.61e-06	0.000188	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—STAT3—psoriasis	6.6e-06	0.000187	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—JUN—psoriasis	6.53e-06	0.000185	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—VEGFA—psoriasis	6.52e-06	0.000185	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—STAT3—psoriasis	6.46e-06	0.000183	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—VEGFA—psoriasis	6.42e-06	0.000182	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—NFKB1—psoriasis	6.37e-06	0.000181	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—STAT3—psoriasis	6.36e-06	0.00018	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CXCL8—psoriasis	6.34e-06	0.00018	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—NFKB1—psoriasis	6.28e-06	0.000178	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TYK2—psoriasis	6.17e-06	0.000175	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CXCL8—psoriasis	6.12e-06	0.000174	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CXCL8—psoriasis	6.09e-06	0.000173	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TYK2—psoriasis	6.07e-06	0.000172	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TYK2—psoriasis	6.06e-06	0.000172	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—IL6—psoriasis	6.03e-06	0.000171	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TYK2—psoriasis	5.94e-06	0.000169	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CXCL8—psoriasis	5.92e-06	0.000168	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—JUN—psoriasis	5.89e-06	0.000167	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CXCL8—psoriasis	5.83e-06	0.000165	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—IL6—psoriasis	5.82e-06	0.000165	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—IL6—psoriasis	5.79e-06	0.000164	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—VEGFA—psoriasis	5.78e-06	0.000164	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—STAT3—psoriasis	5.72e-06	0.000162	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—VEGFA—psoriasis	5.7e-06	0.000162	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—JUN—psoriasis	5.69e-06	0.000161	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NFKB1—psoriasis	5.67e-06	0.000161	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—JUN—psoriasis	5.66e-06	0.000161	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—STAT3—psoriasis	5.64e-06	0.00016	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—APOE—psoriasis	5.64e-06	0.00016	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—IL6—psoriasis	5.63e-06	0.00016	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—IL6—psoriasis	5.54e-06	0.000157	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TYK2—psoriasis	5.52e-06	0.000157	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—JUN—psoriasis	5.5e-06	0.000156	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NFKB1—psoriasis	5.47e-06	0.000155	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NFKB1—psoriasis	5.45e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—JUN—psoriasis	5.42e-06	0.000154	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CXCL8—psoriasis	5.37e-06	0.000152	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NFKB1—psoriasis	5.3e-06	0.00015	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CXCL8—psoriasis	5.28e-06	0.00015	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CXCL8—psoriasis	5.27e-06	0.00015	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NFKB1—psoriasis	5.21e-06	0.000148	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCL8—psoriasis	5.17e-06	0.000147	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—psoriasis	5.15e-06	0.000146	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—psoriasis	5.11e-06	0.000145	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—psoriasis	5.1e-06	0.000145	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—psoriasis	5.03e-06	0.000143	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—psoriasis	5.03e-06	0.000143	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—psoriasis	5.01e-06	0.000142	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—JUN—psoriasis	4.99e-06	0.000142	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—psoriasis	4.97e-06	0.000141	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—psoriasis	4.94e-06	0.00014	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—psoriasis	4.93e-06	0.00014	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—psoriasis	4.92e-06	0.00014	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—psoriasis	4.92e-06	0.00014	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—JUN—psoriasis	4.91e-06	0.000139	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—psoriasis	4.91e-06	0.000139	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—JUN—psoriasis	4.9e-06	0.000139	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—psoriasis	4.89e-06	0.000139	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—psoriasis	4.85e-06	0.000138	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—JUN—psoriasis	4.81e-06	0.000137	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—psoriasis	4.81e-06	0.000136	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—psoriasis	4.81e-06	0.000136	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NFKB1—psoriasis	4.81e-06	0.000136	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—psoriasis	4.76e-06	0.000135	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CAT—psoriasis	4.74e-06	0.000135	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—psoriasis	4.73e-06	0.000134	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NFKB1—psoriasis	4.73e-06	0.000134	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NFKB1—psoriasis	4.72e-06	0.000134	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—psoriasis	4.69e-06	0.000133	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NFKB1—psoriasis	4.63e-06	0.000131	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—psoriasis	4.61e-06	0.000131	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—psoriasis	4.57e-06	0.00013	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—psoriasis	4.51e-06	0.000128	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—JUN—psoriasis	4.47e-06	0.000127	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—psoriasis	4.44e-06	0.000126	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—psoriasis	4.37e-06	0.000124	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—psoriasis	4.36e-06	0.000124	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—psoriasis	4.32e-06	0.000123	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—psoriasis	4.31e-06	0.000122	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NFKB1—psoriasis	4.3e-06	0.000122	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—psoriasis	4.29e-06	0.000122	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—psoriasis	4.28e-06	0.000122	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—psoriasis	4.25e-06	0.000121	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—psoriasis	4.24e-06	0.00012	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—psoriasis	4.2e-06	0.000119	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—psoriasis	4.16e-06	0.000118	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—psoriasis	4e-06	0.000113	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—psoriasis	3.94e-06	0.000112	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—psoriasis	3.91e-06	0.000111	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—psoriasis	3.89e-06	0.00011	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—psoriasis	3.87e-06	0.00011	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—psoriasis	3.75e-06	0.000107	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—psoriasis	3.73e-06	0.000106	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOE—psoriasis	3.69e-06	0.000105	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—psoriasis	3.63e-06	0.000103	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—psoriasis	3.58e-06	0.000101	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—psoriasis	3.56e-06	0.000101	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—psoriasis	3.44e-06	9.76e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—psoriasis	3.42e-06	9.71e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—psoriasis	3.33e-06	9.44e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—psoriasis	3.3e-06	9.36e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—psoriasis	3.27e-06	9.29e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—psoriasis	3.24e-06	9.21e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—psoriasis	3.24e-06	9.19e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—psoriasis	3.21e-06	9.12e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—psoriasis	3.18e-06	9.02e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—psoriasis	3.02e-06	8.57e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—psoriasis	2.97e-06	8.43e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—psoriasis	2.96e-06	8.41e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—psoriasis	2.95e-06	8.38e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—psoriasis	2.91e-06	8.25e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—psoriasis	2.7e-06	7.67e-05	CbGpPWpGaD
